QuantumPharm (2228.HK) introduces Kodexia, an integrated siRNA platform combining sequence design and experimental validation to shorten drug discovery timelines.
XtalPi's launch of the Kodexia platform represents a significant technological advancement by integrating sequence design, chemical modification, and experimental validation into a single workflow. By utilizing in vivo efficacy prediction models, the company aims to drastically accelerate the drug discovery process, positioning itself as a leader in the siRNA therapeutic space.
Kodexia is a novel closed-loop siRNA platform developed by XtalPi that integrates design, chemical modification, and validation into one workflow.
It uses pioneering in vivo efficacy prediction models to streamline the transition from sequence design to experimental validation.
QuantumPharm Inc. (2228.HK) has unveiled Kodexia, a closed-loop siRNA platform designed to streamline the drug development process. The system integrates computational design with experimental validation to enhance in vivo efficacy prediction models.
Kodexia is a closed-loop siRNA platform that integrates computational design, experimental validation, and intellectual property strategy to accelerate drug discovery.